1. Home
  2. TBPH vs MBWM Comparison

TBPH vs MBWM Comparison

Compare TBPH & MBWM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • MBWM
  • Stock Information
  • Founded
  • TBPH 2013
  • MBWM 1997
  • Country
  • TBPH United States
  • MBWM United States
  • Employees
  • TBPH N/A
  • MBWM N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • MBWM Major Banks
  • Sector
  • TBPH Health Care
  • MBWM Finance
  • Exchange
  • TBPH Nasdaq
  • MBWM Nasdaq
  • Market Cap
  • TBPH 699.0M
  • MBWM 740.5M
  • IPO Year
  • TBPH N/A
  • MBWM 1997
  • Fundamental
  • Price
  • TBPH $14.75
  • MBWM $44.13
  • Analyst Decision
  • TBPH Strong Buy
  • MBWM Buy
  • Analyst Count
  • TBPH 4
  • MBWM 4
  • Target Price
  • TBPH $23.00
  • MBWM $52.88
  • AVG Volume (30 Days)
  • TBPH 284.3K
  • MBWM 64.5K
  • Earning Date
  • TBPH 11-10-2025
  • MBWM 10-21-2025
  • Dividend Yield
  • TBPH N/A
  • MBWM 3.45%
  • EPS Growth
  • TBPH N/A
  • MBWM 6.26
  • EPS
  • TBPH 0.26
  • MBWM 5.27
  • Revenue
  • TBPH $77,205,000.00
  • MBWM $233,714,000.00
  • Revenue This Year
  • TBPH $79.82
  • MBWM $10.34
  • Revenue Next Year
  • TBPH N/A
  • MBWM $11.93
  • P/E Ratio
  • TBPH $59.49
  • MBWM $8.35
  • Revenue Growth
  • TBPH 24.49
  • MBWM 5.19
  • 52 Week Low
  • TBPH $7.90
  • MBWM $37.76
  • 52 Week High
  • TBPH $15.34
  • MBWM $52.98
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 58.51
  • MBWM 45.01
  • Support Level
  • TBPH $14.11
  • MBWM $43.23
  • Resistance Level
  • TBPH $15.34
  • MBWM $44.45
  • Average True Range (ATR)
  • TBPH 0.42
  • MBWM 1.34
  • MACD
  • TBPH 0.06
  • MBWM 0.01
  • Stochastic Oscillator
  • TBPH 63.55
  • MBWM 38.66

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About MBWM Mercantile Bank Corporation

Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.

Share on Social Networks: